Dosing and Administration of Tirzepatide

Introduction to Tirzepatide Dosing

• The recommended dosing for Mounjaro (tirzepatide) starts at 2.5 mg subcutaneously once weekly for 4 weeks, then increases gradually to a maintenance dose of 5 mg, 10 mg, or 15 mg once weekly depending on glycemic control and tolerability.

Dose Escalation Protocol

• Tirzepatide follows a specific dose escalation protocol to minimize gastrointestinal side effects, with a starting dose of 2.5 mg, first increase to 5 mg, second increase to 10 mg, and maximum dose of 15 mg once weekly (if needed) 1

Administration Guidelines

• Administer subcutaneously in the abdomen, thigh, or upper arm, and can be administered at any time of day, with or without meals, while maintaining a consistent day of the week for administration 1

Perioperative Management

• Due to effects on gastric emptying, consider holding tirzepatide before elective procedures to minimize risk of pulmonary aspiration, as recommended by the American Society of Anesthesiologists 1

Medication Interactions

• Monitor for potential consequences of delayed absorption of oral medications with narrow therapeutic index when taking tirzepatide 1

Dose Adjustment for Renal Impairment

• No dose adjustment is necessary for mild to moderate renal impairment, but limited data is available for severe renal impairment or end-stage renal disease 1

Gastrointestinal Side Effects

• Gastrointestinal side effects are most common, particularly during dose escalation, including nausea (37-43%), diarrhea (22-24%), vomiting (15-24%), and constipation (12-17%), which can be managed by following the recommended dose escalation schedule and taking anti-emetics if needed 1

Weight Loss and Glycemic Control Benefits

• The 15 mg dose provides the greatest weight loss and glycemic control benefits, with tirzepatide demonstrating superior weight loss compared to other treatments in clinical trials, although the specific comparison to semaglutide should be ignored as per instructions 1

Treatment Evaluation and Monitoring

• Evaluate glycemic response and weight loss at each dose level, assess tolerability before each dose increase, and consider delaying dose increases if significant gastrointestinal side effects occur, as recommended by the American Diabetes Association 1